Royalty Report: Cancer, Diagnostic, Drugs – Collection: 5426

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Cancer
  • Diagnostic
  • Drugs
  • Disease
  • Biotechnology
  • Diagnostic Substances
  • Medical
  • Therapeutic
  • Research

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5426

License Grant
Licensor grants, subject to the terms of this Agreement, to License a worldwide, perpetual and exclusive sublicense to make, use and sell the Protein and Antibodies solely for use with the Mammastatin Serum Assay and  to make, have made, use and sell the Mammastatin Serum Assay and Improvements thereto.

Licensor grants, subject to the terms of this Agreement, to GBI a worldwide, perpetual and non-exclusive sublicense to make, use and create Improvements to Proteins and Antibodies solely in the research, development and sale of additional antibodies and/or diagnostic assays solely for the diagnosis of breast, prostate and/or ovarian cancers.  Also includes  to make, have made, use and create Improvements to the Mammastatin Serum Assay and the Know-How solely in the research, development and sale of Additional Products.

License Property
The Mammastatin Serum Assay is a test to measure Mammastatin levels in the serum of healthy women and breast cancer patients. This assay has been performed in two different formats with different antibody formats.

Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How

P&O TECHNOLOGY shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that BIOTHERAPIES cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.

IPSCIO Record ID: 4246

License Grant
Licensor grants, subject to the terms of this Agreement, to Licensee a worldwide, perpetual and exclusive license to make, have made, use and create improvements to the P&O Technology, Know-How and Improvements thereto to make, have made, use, market and sell Licensed Products.
License Property
Licensee shall have the right to grant sublicenses under the license granted herein.

Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How .

Field of Use
P&O Technology shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that Biotherapies cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.

IPSCIO Record ID: 26530

License Grant
The Company signed a license agreement with the University for the exclusive rights of Mammastatin technology.
License Property
Mammastatin is a protein that has been found to be present in relatively higher levels in the breast tissue of healthy women as compared to those women that eventually have developed breast cancer.
Field of Use
The Comany developed the MSA test as a simple blood serum diagnostic that could measure the quantity of Mammastatin in blood serum using monoclonal antibody technology, whereby the results from that test could then be used to assess women’s risk of developing breast cancer.

IPSCIO Record ID: 27493

License Grant
The University hereby grants to Licensee the exclusive, worldwide license under the Licensed Patents to make, have made, use, market and sell Products; biological materials covering (i) the human mammary cell growth inhibitor protein known as mammastatin, the aene encodin, such protein, and methods of making and using same, Human Mammary ‘Cell Growth Inhibitor Protein and Mammastatin – A Mammary Cell Growth Inhibitor and (ii) monoclonal antibodies directed against the protein known as mammastatin, and methods of making and using same, Monoclonal Anti-bodies to Human Mammary Cell Growth Inhibitor.
License Property
'Mammastatin' means a protein produced by the normal mammary gland (breast) in humans  that  controls  the  growth of breast  cancer  cells,  as more  fully described under the discussion of 'Technology' contained in the License.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 6345

License Grant
The Company grants an exclusive, worldwide, royalty-bearing License, with the right to subLicense, to make, have made, use, sell and import Licensed Products, which includes finished products used for the detection of the Company’s proprietary prostate cancer biomarkers in both urine and biopsied prostate tissue for differentiating clinically significant prostate cancer from other prostate conditions, and to use Patent Rights and Know-How covering the prostate cancer biomarkers.
License Property
Licensed Product(s) shall mean finished products consisting of one or more nucleic acid detection reagents for the assay of one or more Prostate Marker(s) for use in the Field, the manufacture, use, sale or importation of which, but for the rights granted herein, would infringe a Valid Claim within Patent Rights.

U.S.
7,117,188
Method of Identifying Patterns in Biological Systems and Uses Thereof

U.S.
12/025,724
Biomarkers Upregulated in Prostate Cancer

U.S.
12/242,264
Biomarkers Overexpressed in Prostate Cancer

U.S.
12/327,823
Methods for Screening, Predicting and Monitoring Prostate Cancer

U.S.
12/349,437
Methods for Screening, Predicting and Monitoring Prostate Cancer

Field of Use
Field shall mean the use of a molecular diagnostic assay using the Licensed Prostate Markers in in vitro diagnostics relating to prostate cancer, including the detection of the presence or risk of prostate cancer, or the selection of therapy, or in a Research Application related to prostate cancer.

IPSCIO Record ID: 5297

License Grant
Licensor hereby grants the right to use MoAb 7E11-C.5.3 solely for such purposes.
License Property
The term 'MoAb 7E11 shall mean and collectively include that certain antibody to PSMA known as MoAb 7E11-C5, which such antibody is claimed in United States Patent No 5,162,504, granted November 10, 1992, and entitled 'Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostate Cancer Patients.'  One subclone of MoAb 7E11 is MoAb 7E11-C5.3.  To enable the licensee to utilize MoAb 7E11-C 5.3 in connection with the development, manufacturing, testing, or conducting quality control tests on Licensed Products and to practice Licensed Processes.
Field of Use
The term 'PSMA' shall mean prostate specific membrane antigen and shall include the PSMA protein.

The term 'PSMP' shall mean prostate specific membrane peptides which shall include any peptide sequence appearing within the PSMA protein.

The term 'Licensed Products' shall mean products for the immunotherapy of prostate cancer which are produced by [  ***  ], with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP.

The term 'Licensed Processes' shall mean any process for the immunotherapy of prostate cancer in patients by [  ***  ] including, but not limited to [  ***  ], ex vivo, with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP, and [  ***  ] the use or practice of which would, but for the licenses granted herein, infringe one or more Valid Claims of an issued patent or pending patent application included in SKICR Patent Rights.

IPSCIO Record ID: 223141

License Grant
The German Licensor hereby grants to Licensee an exclusive license (including the right to grant sublicenses) under the Licensed Patent Rights to conduct research and to develop, make, use, offer for sale, sell and import Licensed Products and to provide Services in the Territory.
License Property
Licensed Patent Rights shall mean (a) those certain patent applications and patents listed hereto; (b) all patents that have issued or in the future issue from such foregoing patent applications, including utility, model and design patents and certificates of invention; (c) all patents that have issued or in the future issue from any patent application that claims priority from, or common priority with, any of the foregoing patent applications, including utility, model and design patents and certificates of invention; and (d) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such foregoing patent
applications and patents.

W003023057 (PCT /EP02/05489) – Method and Diagnosis Kit for Selection and/or for Qualitative and/or Quantitative Detection of Cells

Licensed Products shall mean in-vitro diagnostic assays to isolate, detect, identify, quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care, the  manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the AdnaGen Patent Rights.

Field of Use
This agreement pertains to the medical industry relating to certain technology concerning the qualitative and quantitative detection of cells which may be useful in connection with nucleic acid diagnostic assays. The diagnostic indicators are used for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care.

'Group 1 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of kidney cancer, cervical cancer, and/or ovarian cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.

'Group 2 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of lung cancer, colon cancer, and/or breast cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.

IPSCIO Record ID: 26501

License Grant
The Canadian Licensor hereby grants to Licensee a worldwide, exclusive license and sublicense (including the right to grant sublicenses) in the Field under the Licensed IP Rights to research, develop, make, have made, use, offer for sale, sell and import Licensed Products, and practice Licensed Methods, in each case for the detection and/or measurement of PCA3(DD3) as a marker for the diagnosis monitoring, prognosis, or drug susceptibility of prostate cancer.
License Property
The Licensor owns or has intellectual property rights with respect to the PCA3(DD3) gene (as defined below) and certain related technology.

APTIMA(R) Technology shall mean all technology reasonably necessary to make or use Licensee's APTIMA generation of amplified nucleic acid assays, including Target Capture (TC), Transcription-Mediated Amplification (TMA), Hybridization Protection Assay (HPA) and Dual Kinetic Assay (DKA) technologies, each to the extent in each case that Licensee has a right to license or sublicense.

The technology is a diagnostic technology (genetic) for the early warning of prostate cancer.

The licensor's (Quebec, Canada) urine test (PCA3) to detect the genetic marker of prostate cancer is now being developed by the licensee based in San Diego, and after more clinical trials a new version will hit the market by year end (2005).

Field of Use
Field shall mean the detection and/or measurement of PCA3(DD3) as (a) a marker for the diagnosis, monitoring, prognosis, or drug susceptibility of prostate cancer; and/or (b) a marker for cancer (without limitation).  The Field shall not include the use of any assay in drug discovery.

IPSCIO Record ID: 5926

License Grant
The Licensor hereby grants to Licensee a royalty-bearing, exclusive license under licensed subject matter to manufacture, have manufactured, use, import, offer to sell and/or sell Licensed Products within Licensed Territory for use within Licensed Field.

Licensee entered into a License and Technology Licensing Agreement with a University's Cancer Center to commercialize technology developed for cancer detection in animals and humans based on a tumor marker known as p65 which has been demonstrated to show elevated levels in the blood of canine and human cancer patients.

License Property
MDA89-015, which consists of the following three patents 'Tumor Marker Protein and Antibodies Thereto for Cancer Risk Assessment or Diag- nosis,' U.S. Patent No. 5,310,653, Issued May 10, 1994, Inventors Margaret Hanausek-Walaszek; Thomas J. Slaga; Zbigniew Walaszek.

'Diagnostic and Premonitoring Uses of a 65 kDa Tumor-Associated Protein in Com- panion and Domestic Animal Malignancy,' U.S. Patent No. 5,411,868, Issued May 2, 1995; Inventors Margaret Hanausek-Waluszek; Lezlee Coghlan.

'Tumor Marker Protein for Cancer Risk Assessment, U.S, Patent No. 5,773,215, Issued June 30, 1998, Inventors Margaret Hanausek-Walaszek; Thomas J. Slap; and Zbigniew Walaszek.

IPSCIO Record ID: 28150

License Grant
The Company engages the Consultant to continue the research and development of the ebaf assay.  The Consultant agrees to devote his full time good faith efforts to continue the research and development and validation of the uses of the ebaf assay and such other duties and tasks as may be assigned by the Company from time to time.
Field of Use
The ebaf assay can be used for the following purposes; (a) diagnostic screening test for colon cancer; (b) diagnostic screening test for ovarian cancer; (c) diagnostic screening test for bladder cancer; (d) Method for inducing growth and enhancing survival of nervous tissue; (e) Inhibition of TGF-Beta and Uses Thereof [US09/679,971]; and (f) Method for Promoting Hair Growth.

IPSCIO Record ID: 4950

License Grant
Licensor grants the Licensee an exclusive worldwide license to conduct research on the development of laboratory assay kits for the screening of colon, ovarian and testicular cancer.
License Property
Licensed Products shall mean assay kits for the screening of colon, ovarian and testicular cancer, covered by a claim of any unexpired NSUH Patent.
Field of Use
Field shall mean screening assays for colon, ovarian and testicular cancer.

IPSCIO Record ID: 251135

License Grant
The parties entered into a nonexclusive license agreement on the patented ChemoFx technology.
License Property
ChemoFx ®, is a proprietary drug response marker which measures an individuals malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Newly published prospective data demonstrates a 14 -month improvement in overall survival (OSI and improved progression free survival (PFS) when ovarian cancer patients are treated with responsive therapies as indicated by ChemoFx ®.
Field of Use
The ChemoFx assay is an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy.

IPSCIO Record ID: 26038

License Grant
The Licensor grants to Licensee a non-exclusive right and license, without the right to sublicense, under the Licensed Patent Rights as licensed to Licensor pursuant to the Original Agreement, to make, have made, use, sell, offer for sale and import Licensed Products and to practice the Licensed Methods in the Field in the Territory to the extent permitted by law.
License Property
The Licensor is involved in the discovery, development and commercialization of medical tests that diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases. Field shall mean in-vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.
Field of Use
The Licensee is a provider of clinical laboratory services.

Field” shall mean in vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.